Pragmatic randomized trial of Shingrix to prevent major adverse cardiovascular events and dementia in adults ≥65 years

Phase 4, randomised, open-label trial of Zoster vaccine recombinant in herpes zoster (HZ), major adverse cardiac events (MACE), Dementia and 2 more (2 arms), sponsored by GSK. Primary endpoints: Hospitalization for major adverse cardiovascular events (MACE) and New dementia. Planned start Apr 2026; status: authorised.